Last reviewed · How we verify

Durvalumab, Gemcitabine, Cisplatin

Akeso · Phase 3 active Small molecule

Durvalumab, Gemcitabine, Cisplatin is a PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) Small molecule drug developed by Akeso. It is currently in Phase 3 development for Unresectable or metastatic biliary tract cancer, Potentially resectable or unresectable pancreatic cancer (in development).

This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.

This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death. Used for Unresectable or metastatic biliary tract cancer, Potentially resectable or unresectable pancreatic cancer (in development).

At a glance

Generic nameDurvalumab, Gemcitabine, Cisplatin
SponsorAkeso
Drug classPD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin)
TargetPD-L1 (durvalumab); DNA (gemcitabine and cisplatin)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Durvalumab is a PD-L1 inhibitor that restores anti-tumor T-cell immunity by blocking the interaction between PD-L1 on tumor cells and PD-1 on immune cells. Gemcitabine and cisplatin are chemotherapy agents that directly damage tumor DNA and induce apoptosis. The combination leverages chemotherapy's immunogenic cell death to enhance durvalumab's checkpoint inhibition effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Durvalumab, Gemcitabine, Cisplatin

What is Durvalumab, Gemcitabine, Cisplatin?

Durvalumab, Gemcitabine, Cisplatin is a PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) drug developed by Akeso, indicated for Unresectable or metastatic biliary tract cancer, Potentially resectable or unresectable pancreatic cancer (in development).

How does Durvalumab, Gemcitabine, Cisplatin work?

This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.

What is Durvalumab, Gemcitabine, Cisplatin used for?

Durvalumab, Gemcitabine, Cisplatin is indicated for Unresectable or metastatic biliary tract cancer, Potentially resectable or unresectable pancreatic cancer (in development).

Who makes Durvalumab, Gemcitabine, Cisplatin?

Durvalumab, Gemcitabine, Cisplatin is developed by Akeso (see full Akeso pipeline at /company/akeso).

What drug class is Durvalumab, Gemcitabine, Cisplatin in?

Durvalumab, Gemcitabine, Cisplatin belongs to the PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) class. See all PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) drugs at /class/pd-l1-inhibitor-combined-with-chemotherapy-gemcitabine-and-cisplatin.

What development phase is Durvalumab, Gemcitabine, Cisplatin in?

Durvalumab, Gemcitabine, Cisplatin is in Phase 3.

What are the side effects of Durvalumab, Gemcitabine, Cisplatin?

Common side effects of Durvalumab, Gemcitabine, Cisplatin include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Fatigue, Immune-related adverse events (pneumonitis, hepatitis).

What does Durvalumab, Gemcitabine, Cisplatin target?

Durvalumab, Gemcitabine, Cisplatin targets PD-L1 (durvalumab); DNA (gemcitabine and cisplatin) and is a PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin).

Related